CD4 and cancer: Recent advances have established proof of concept in the following fields: Scientists found that a sizable fraction of non-synonymous cancer mutations were immunogenic when delivered by messenger RNA, and that CD4 + T cells were the preeminent population capable of recognizing these abnormalities [179].